MONDAY, JUNE 21

Welcoming Remarks and Keynote Address (7am Denver/Mountain Time Start)

Klaus P. Hoeflich, Nested Bio, USA
Charles L. Sawyers, Memorial Sloan-Kettering Cancer Center, USA

Lineage Plasticity: Lessons from Prostate Cancer

Clinical Genomics (7:40am Denver/Mountain Time Start)

Scott W. Lowe, Memorial Sloan Kettering Cancer Center, USA
Todd R. Golub, Broad Institute, USA

Pre-Clinical Approaches to Cancer Precision Medicine

Leukemia Genomics

Jaclyn A. Biegel, Children’s Hospital Los Angeles and Keck School of Medicine of USC, USA

Personalized Genomic Testing in Pediatric Oncology

Targeting Novel Mechanisms (9:15am Denver/Mountain Time Start)

Todd R. Golub, Broad Institute, USA
John V. Heymach, University of Texas MD Anderson Cancer Center, USA

LKB1/STK11 Axis in Precision Immunotherapy

Non-Cell Autonomous Tumor Control via Senescence

Structural Basis for the Action of Clinical MEK Inhibitors at KSR-Bound MEK

Short Talk: Eganelisib (IPI-549) Activity as a Macrophage Reprogramming Therapeutic Candidate in 1L Metastatic TNBC, 2L Metastatic Urothelial Cancer and Other Solid Tumors

Short Talk: SCD1-Regulated Ferroptosis as a Novel Therapeutic Strategy in Non-Small Cell Lung Cancer

Poster Session (12pm Denver/Mountain Time Start)

TUESDAY, JUNE 22

Emerging Technologies I (7am Denver/Mountain Time Start)

Alice T. Shaw, Novartis Institutes for Biomedical Research, Inc., USA
Valsamo Anagnostou, Johns Hopkins University School of Medicine, USA

Harnessing Tumor Evolution and Immune Responses to Treat Lung Cancer

Gromoslaw A. Smolen, Celsius Therapeutics, USA

Single Cell Genomics Technologies in the Clinic – Challenges and Opportunities

Nicola Aceto, ETH Zürich, Switzerland

Biology and Vulnerabilities of Circulating Tumor Cells

Wednesday, June 23

Emerging Technologies II (7am Denver/Mountain Time Start)

Jason S. Carroll, Cancer Research UK, University of Cambridge, UK
Priti Hegde, Foundation Medicine, USA

Driving Precision Medicine through Clinical Computational Oncology

Russell W. Jenkins, Massachusetts General Hospital, USA

Organotypic Modeling of Cancer and Immune Cell Dynamics

Nir Yosef, University of California, Berkeley, USA

Inferring and Making Sense Out of Cancer Cell Phylogenies

Nathanael Gray, Stanford University, USA

Targeted Protein Degradation- A New Approach for Challenging Targets

Hannah Julia Uckelmann, Dana-Farber Cancer Institute, USA

Short Talk: MLL-Menin Inhibition Reverses Pre-leukemic Progenitor Self-renewal in NPM1 Mutant AML

Targeting Gene Transcription (9:10am Denver/Mountain Time Start)

Russell W. Jenkins, Massachusetts General Hospital, USA
Christopher Vakoc, Cold Spring Harbor Laboratory, USA

Transcription Factor Addiction

*Jason S. Carroll, Cancer Research UK, University of Cambridge, UK

Proteomic Analysis of Chromatin Remodeling Complexes

Trudy G. Oliver, Huntsman Cancer Institute, USA

Using GEMMs to Identify Therapeutic Vulnerabilities in MYC-Driven Small Cell Lung Cancer

Scott A. Armstrong, Dana-Farber Cancer Institute, USA

Targeting the MLL Complex to Control Gene Expression

Timothy Heffernan, MD Anderson Cancer Center, USA

PRMT1: A Novel Dependency at the Nexus of RNA Metabolism and Cancer

Networking Lounge (11:15am Denver/Mountain Time Start)

THURSDAY, JUNE 24

Novel Therapeutics (7am Denver/Mountain Time Start)

*Scott W. Lowe, Memorial Sloan Kettering Cancer Center, USA

Mechanisms of Resistance to Combined Inhibition of RAS Signaling plus Autophagy in Pancreatic Cancer

*Klaus P. Hoeflich, Nested Bio, USA

Targeting Protein Kinases in Cancer

Neal Rosen, Memorial Sloan-Kettering Cancer Center, USA

A General Allele-Specific Model for Understanding and Treating Tumors Driven by ERK-Activation

Alberto Bardelli, University of Torino, Italy

High Dose Vitamin C and Inactivation of DNA Repair Boost Cancer Immunotherapy

Radha Mukherjee, 275.00

Short Talk: Regulation of PTEN Translation by PI3K Signaling Maintains Pathway Homeostasis

Jordan Young, 275.00

Short Talk: Oncogenic CCNE1 Amplification Is Synthetic Lethal with PKMYT1 Kinase Inhibition

The Future of Precision Oncology (9:35am Denver/Mountain Time Start)

*Klaus P. Hoeflich, Nested Bio, USA

*Scott W. Lowe, Memorial Sloan Kettering Cancer Center, USA

Elaine R. Mardis, Nationwide Children's Hospital, USA

Informing Patient Treatment with Clinicogenomic Data

Naoko Takebe, NCI, National Institutes of Health, USA

NCI’s Precision Medicines Initiatives

Career Roundtable (12:30pm Denver/Mountain Time Start)

Charles L. Sawyers, Memorial Sloan-Kettering Cancer Center, USA

Christopher Vakoc, Cold Spring Harbor Laboratory, USA

Tracy T. Tang, 275.00

* Session Chair † Invited but not yet accepted     Program current as of September 19, 2021.
For the most up-to-date details, visit https://www.keystonesymposia.org.